These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21957991)

  • 21. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.
    Kruczynski A; Poli M; Dossi R; Chazottes E; Berrichon G; Ricome C; Giavazzi R; Hill BT; Taraboletti G
    Eur J Cancer; 2006 Nov; 42(16):2821-32. PubMed ID: 16973349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinflunine.
    Shnyder SD
    IDrugs; 2004 Sep; 7(9):851-9. PubMed ID: 15470603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C; Agerbaek M; Von Der Maase H
    Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium.
    Hainsworth JD; Meluch AA; Lane CM; Spigel DR; Burris HA; Gandhi JG; Crane EJ; Stipanov MA; Greco FA
    Cancer Invest; 2010 Mar; 28(3):275-9. PubMed ID: 20158340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
    Lobert S; Puozzo C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.
    Shnyder SD; Cooper PA; Gyselinck N; Hill BT; Double JA; Bibby MC
    Anticancer Res; 2003; 23(6C):4815-20. PubMed ID: 14981930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in vinca-alkaloids: Navelbine.
    Marty M; Extra JM; Espie M; Leandri S; Besenval M; Krikorian A
    Nouv Rev Fr Hematol (1978); 1989; 31(2):77-84. PubMed ID: 2671933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of upper urinary tract urothelial carcinoma.
    Sun M; Abdo A; Abdollah F; Schmitges J; Thuret R; Jeldres C; Shariat SF; Perrotte P; Karakiewicz PI
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1955-65. PubMed ID: 21110761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.